

OcuMension

Ophthalmological Intergrated Solution

Sep-2021

Virtus et Lumen
勇气和光明

All the information in this presentation has been provided by the Company and has not been independently verified by its advisers, agents, representatives, underwriters or any of their respective affiliates or associates (collectively, "advisers"). No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company or any of its subsidiaries or by its advisers or representatives as to the fairness, accuracy, completeness or correctness of, this presentation or any other written or oral information made available to any interested party or its advisers and any liability therefore is hereby expressly disclaimed.


The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. By their nature forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There may be additional material risks that are currently not considered to be material or of which the Company and its advisers or representatives are unaware. Against the background of these uncertainties, readers should not rely on these forward-looking statements. The Company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation is confidential and must not be copied, reproduced, distributed or passed (in whole or in part) to any other person at any time without the prior written consent of the Company or its advisers.

By accepting this presentation the recipient has agreed, upon request, to return promptly all material received from the Company or its advisers (including this presentation) without retaining any copies. In furnishing this presentation, the Company and its advisers or representatives undertake no obligation to provide the recipient with access to any additional information or to update this presentation or to correct any inaccuracies therein which may become apparent.

The distribution of this presentation in any jurisdiction may be restricted by law and persons in possession of this presentation should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.

Any prospective purchaser interested in buying securities of or evaluating the Company is recommended to seek its own independent legal, tax, financial and other professional advice.





100 salespersons planned by 2021, eye disease specialized salesforce



Manufacturing site with total annual capacity of **455 Million** Doses



6 Phase III clinical trials in China, **2** Real-World Studies in China




20 assets focusing on first- or best-in-class ophthalmic therapies including **6** FDA approved drugs



The **first** time that NMPA accepted NDA based on real world study data——YUTIQ®

Collaborations Around the World






1. OT-101 which is first atropine MRCT study including the Chinese population.
 2. It is the first time that NMPA has accepted the new drug application based on real world study data.

Program	Mode of Action	Indication	Commercial Rights	Partners	Pre-IND	Phase I / II	Phase III	NDA / BLA
OT-401 (YUTIQ [®])	Fluocinolone acetonide intravitreal implant	Chronic NIU-PS ¹	Greater China, Korea and 11 countries in Southeast Asia	EYEPOINT PHARMACEUTICALS	China			USA Approved (EyePoint)
OT-1004 (Emadine [®])	Emedastine difumarate	Allergic conjunctivitis	China's mainland	NOVARTIS				Commercialized
OT-305 (Betoptic [®] S)	Betaxolol hydrochloride	Glaucoma and ocular hypertension	China's mainland	NOVARTIS				Commercialized
OT-204 (欧沁 [®]) ²	Sodium hyaluronate	Dry eye	China's mainland	汇恩兰德 HUONLAND				Commercialized
OT-303 ³	Brimonidine tartrate	Glaucoma and ocular hypertension	China's mainland	汇恩兰德 HUONLAND				Commercialized
OT-601	Moxifloxacin	Bacterial conjunctivitis	Global		China			
OT-101	Low-concentration atropine	Myopia	Global		Global			
OT-301 (NCX 470 [®])	NO-donating prostaglandin analog	Glaucoma and ocular hypertension	Greater China, Korea and 12 countries in Southeast Asia	nicox visible science	Global			
OT-1001 (ZERVIATE [®])	Cetirizine hydrochloride	Allergic conjunctivitis	Greater China and 11 countries in Southeast Asia	nicox visible science	China			USA Approved (Nicox)
OT-702	Anti-VEGF	wAMD	Mainland China	LuYe Pharma 绿叶制药	China			
OT-502 (DEXYCU [®])	Dexamethasone	Postoperative inflammation	Greater China, Korea and 11 countries in Southeast Asia	EYEPOINT PHARMACEUTICALS	China			USA Approved (EyePoint)
OT-202	Tyrosine kinase inhibitor	Dry eye	Global		China			
OT-503 (NCX 4251 [®])	Fluticasone propionate nanocrystals	Blepharitis	Greater China	nicox visible science	China	Phase II USA completed (Nicox)		
OT-701	Anti-VEGF	wAMD	Greater China	SENJU GENE TECHNO SCIENCE	China		Phase III Japan completed (Senju and GTS)	
OT-703	Fluocinolone intravitreal implant	DME	Greater China, Korea and 11 countries in Southeast Asia	ALIMERA SCIENCES	China			USA Approved (Alimera)
OT-601-C	Moxifloxacin-dexamethasone sodium phosphate	Postoperative inflammation	Global		China			
OT-302	Acetazolamide	Acute glaucoma	Global		China			
OT-1301	Cyclosporine implant	Cornea graft rejection	Global		China			
OT-1601	Stem cells	Retinitis pigmentosa and dry AMD	Greater China	SanBio	China			
OT-1602	Stem cells	Optic neuritis	Greater China	SanBio	China			

■ In-licensed/acquired ■ Internally developed

1. Non-infectious uveitis affecting the posterior segment of the eye
 2. We acquired Ou Qin from Huonland and are entitled to all drug registration certificates and data related to Ou Qin. We plan to register ourselves as the MAH of Ou Qin.
 3. We are the exclusive sales agent of Brimonidine Tartrate Eye Drops in Mainland China. Huonland is the drug registrant and registered manufacturer of Brimonidine Tartrate Eye Drops.
 4. May not require Phase I and Phase II clinical trials prior to beginning Phase III clinical trials.
 5. May not require Phase I clinical trials prior to beginning Phase II clinical trials.





OT-101

- Low concentration (0.01%) atropine eye drop
- Delay the progression of myopia
- A Phase III Multi Regional Clinical Trial
- Innovative closed-loop split device to address stability issues for low-concentration atropine solutions
- In-house



OT-202

- Tyrosine kinase inhibitor eye drop
- Treat for dry eye
- IND submitted
- Novel mechanism of action to reduce inflammation in dry eye by targeting tyrosine kinases
- In-house



OT-301 (NCX 470)

- NO-donating prostaglandin analog eye drop
- Treat for glaucoma and ocular hypertension
- A Phase III Multi Regional Clinical Trial
- Dual mechanism of action to activate two independent aqueous humor outflows
- Licensed from Nicox



OT-502 (DEXYCU®)

- Dexamethasone intraocular suspension
- Treat for postoperative inflammation
- A Phase III Clinical Trial in China
- First and only FDA-approved long-acting intraocular product for the indication
- Licensed from Eyepoint



OT-401 (YUTIQ®)

- Fluocinolone acetonide intravitreal implant
- Treat for chronic NIU-PS
- NDA accepted
- First and only FDA-approved implant with up to three years of efficacy
- Licensed from Eyepoint



OT-1001 (ZERVIAE®)

- Antihistamine cetirizine hydrochloride eye drop
- Treat for allergic conjunctivitis
- A Phase III Clinical Trial in China
- First and only antihistamine approved for children aged 2+ years
- Licensed from Nicox



欧沁®



Emadine®



Betoptic®S



康株®

	欧沁®	Emadine®	Betoptic®S	康株®
Overview	<ul style="list-style-type: none"> 0.3% sodium hyaluronate eye drop 0.8ml single-dose Free of preservatives 	<ul style="list-style-type: none"> Emedastine difumarate eye drop A relatively selective, H1-receptor antagonist Included in the National Health Insurance Drug List 	<ul style="list-style-type: none"> Betaxolol hydrochloride eye drop A competitive, beta (1)-selective adrenergic antagonist Included in the National Health Insurance Drug List 	<ul style="list-style-type: none"> Aqueous solution containing 0.02% chlorhexidine gluconate Alcohol free Imported from Japan
Indication	<ul style="list-style-type: none"> Dry eye 	<ul style="list-style-type: none"> Allergic conjunctivitis 	<ul style="list-style-type: none"> Open-angle glaucoma and ocular hypertension 	<ul style="list-style-type: none"> Eyelid disinfection
Commercialization Timeline	<ul style="list-style-type: none"> In April 2020 	<ul style="list-style-type: none"> In August 2021 	<ul style="list-style-type: none"> In August 2021 	<ul style="list-style-type: none"> In December 2020
Epidemiology	<ul style="list-style-type: none"> 234.9 million dry eye disease patients in China in 2019 	<ul style="list-style-type: none"> 250.6 million allergic conjunctivitis patients in China in 2019 	<ul style="list-style-type: none"> 8.6 million open-angle glaucoma patients in China in 2019 	<ul style="list-style-type: none"> Consumer goods

TRIAL PRODUCTION IN SUZHOU MANUFACTURING SITE AT THE END OF 2021



4 workshops planned with maximum production capacity of 455 million doses



Highly smart and intelligent facilities requiring less than 130 workers when running at full capacity



Production lines tailored for ophthalmic medicine and compliant with GMP requirements of China, US and EU



Outstanding location
Supply chain with fast response

